Company Overview
Longeveron Inc. operates as a clinical stage biotechnology company dedicated to developing cellular therapies designed to address aging-related and life-threatening conditions within the United States market. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry where it seeks to advance allogeneic mesenchymal stem cell formulations like LOMECEL-B. In terms of scale, the firm maintains a market capitalization of $26.94M, generates annual revenue of $1.20M, and employs a workforce of 38 individuals. These valuation and revenue figures indicate that the company is a micro-cap entity with limited revenue generation relative to its market valuation, suggesting a high reliance on future clinical milestones or external capital to sustain operations rather than current commercial profitability. The small employee count of 38 further contextualizes the company as a lean organization typical of early-stage biotech firms concentrating resources on research and development.
Financial Health
The company reported revenue of $1.20M over the trailing twelve months, yet recorded a net income of $-22,704,000 and an EBITDA of $-22,061,000, revealing a significant structural gap where operating expenses vastly exceed revenue generation. This disparity indicates a cost structure heavily weighted toward research, development, and clinical trial expenditures that have not yet been offset by commercial sales. Free cash flow stands at $-11,171,375, which highlights a substantial cash burn rate that limits the company's immediate financial flexibility and necessitates ongoing access to capital markets or private funding. Margins across the business reflect this early-stage dynamic, with a gross margin of 67.0% suggesting favorable cost of goods sold relative to revenue, contrasted by an operating margin of -1479.2% and a profit margin of 0.0% that underscore deep operational losses. The balance sheet presents a mixed picture with total cash holdings of $4.66M against total debt of $824,000, resulting in a debt-to-equity ratio of 14.52. While the absolute debt amount is modest, the high debt-to-equity ratio reflects the capitalization structure often found in loss-making biotech firms where equity dilution is used to manage leverage. Short-term liquidity is supported by a current ratio of 1.33, indicating the company possesses sufficient current assets to cover its current liabilities, though the margin is relatively tight given the negative cash flow. Return metrics demonstrate the financial pressure on the firm, with a return on equity of -164.7% and a return on assets of -81.3%, which reveal that management has not yet achieved positive returns on the capital deployed into the business.
Valuation Assessment
Valuation multiples for Longeveron Inc. are distorted by its lack of profitability, showing a P/E Ratio (TTM) of N/A and a forward P/E of -0.60, which implies that earnings are negative and traditional trailing price-to-earnings metrics are not applicable. The price-to-book ratio stands at 3.72, indicating that the market values the company at a premium of 3.72 times its tangible book value, a common scenario for firms with intangible assets or significant future growth potential not yet reflected in book value. Alternative valuation metrics such as the price-to-sales ratio of 22.47 and an EV/EBITDA of -0.80 further illustrate that investors are pricing the stock based on revenue multiples and enterprise value rather than current earnings power. Price action shows a 52-week high of $1.92 and a 52-week low of $0.47, placing the current trading range within a wide band of volatility typical for speculative biotech stocks. The beta value of 0.28 suggests that the stock price exhibits low volatility relative to the broader market, moving significantly less than the market index during periods of stability or turbulence.
Growth & Income
Revenue growth (YoY) is recorded at -39.5%, while earnings growth (YoY) is N/A due to the company's continued losses, indicating that the firm is in a contractionary revenue phase rather than a growth phase. Because the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders but instead retains all available capital to fund its research and development pipeline. This reinvestment strategy is standard for clinical stage biotechnology companies that prioritize expanding their therapeutic portfolio over providing immediate income to investors. The overall growth and income profile is characterized by declining revenue and zero income distribution, reflecting a business model focused entirely on long-term product development rather than current commercial expansion or shareholder returns.